SCHEMBL5653949

SCHEMBL5653949

CCc1cnc(NC(=O)C(F)(F)F)s1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNE1 P24864 3/20 0.55
CDK2 P24941 3/20 0.55
CDK5 Q00535 2/20 0.55
FDPS P14324 1/20 0.49
MEN1 O00255 4/20 0.40
KMT2A Q03164 4/20 0.40
ALDH1A1 P00352 3/20 0.40
PKM P14618 1/20 0.40
HTT P42858 1/20 0.40
HIF1A Q16665 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
TSHR P16473 1/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
FFAR2 O15552 1/20 0.40
LMNA P02545 3/20 0.40
KDM4E B2RXH2 1/20 0.40
NPC1 O15118 1/20 0.40
HPGD P15428 1/20 0.40
NFKB1 P19838 1/20 0.40
RAB9A P51151 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10864137 0.84 FFAR2 (0.40) CCNE1CDK2CDK5MEN1KMT2A
SCHEMBL23213713 0.82 CCNE1 (0.66) CCNE1CDK2CDK5FDPSMEN1
SCHEMBL5680451 0.81 CCNE1 (0.39) CCNE1CDK2CDK5MEN1KMT2A
SCHEMBL233711 0.80 CDK2 (0.60) CCNE1CDK2CDK5FDPSMEN1
SCHEMBL5652094 0.79 RAB9A (0.54) MEN1KMT2APKMSMN1; SMN2LMNA
SCHEMBL5653356 0.79 CCNE1 (0.39) CCNE1CDK2CDK5MEN1KMT2A
SCHEMBL5653937 0.78 CCNE1 (0.38) CCNE1CDK2CDK5MEN1KMT2A
SCHEMBL11224487 0.78 CCNE1 (0.61) CCNE1CDK2CDK5FDPSMEN1
SCHEMBL10864376 0.77 PSEN1 (0.36) CCNE1CDK2CDK5MEN1KMT2A
SCHEMBL2652269 0.77 FFAR2 (0.57) CCNE1CDK2CDK5MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070105908-A1 Thiazolimine compound and oxazolimine compound DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2007-05-10 US disclosed
EP-1640369-A1 THIAZOLIMINE COMPOUND AND OXAZOLIMINE COMPOUND Dainippon Sumitomo Pharma Co., Ltd. (JP) 2006-03-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105908-A1 Thiazolimine compound and oxazolimine compound CMA1, TH, NPR3 CCNE1 290/4885CDK2 488/4885CDK5 1226/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.